Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978222 · ClinicalTrials.gov registry record · Phase 2
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
A Phase 2 study, sponsored by Marker Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT02978222 is a Phase 2 study that was terminated before completion, run by Marker Therapeutics. The registered enrollment target is 120 participants.
The verdict
NCT02978222, a Phase 2 study, was terminated before completion, sponsored by Marker Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, parallel groups Phase II trial. Patients with platinum-sensitive advanced ovarian cancer, defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regimen. Patients will be randomized to either the vaccine regimen with GM-CSF adjuvant or GM-CSF adjuvant alone as a control group. Treatment will be administered as a consolidation therapy within one year of the last administration of platinum, targeting the first remission.
Interventions
- BIOLOGICAL FRα peptide plus Adjuvant (GM-CSF)
- DRUG Adjuvant (GM-CSF) Alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2020-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02978222
The ClinicalTrials.gov registry entry for NCT02978222 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marker Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FRα peptide plus Adjuvant (GM-CSF) is the first listed.
NCT02978222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02978222 about?
NCT02978222 is a clinical study titled "Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer". This is a double-blind, randomized, parallel groups Phase II trial. Patients with platinum-sensitive advanced ovarian cancer, defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regim...
What is the current status of trial NCT02978222?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2017-07-20. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT02978222?
The interventions under investigation include: FRα peptide plus Adjuvant (GM-CSF) (BIOLOGICAL), Adjuvant (GM-CSF) Alone (DRUG).
Who is sponsoring clinical trial NCT02978222?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.